Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M |
| Total Depreciation and Amortization | 135.00K | 68.00K | 34.00K | 33.00K | 34.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.36M | 20.84M | -33.09M | -113.45M | 116.32M |
| Change in Net Operating Assets | 1.20M | -612.00K | -1.51M | -1.33M | -1.26M |
| Cash from Operations | -9.46M | -15.04M | -11.53M | -16.28M | -6.20M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | 0.00 | 0.00 | 356.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | 0.00 | 0.00 | 356.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 69.44M | 0.00 | 0.00 | 115.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.73M | 0.00 | -472.00K | -7.01M |
| Cash from Financing | -- | 67.71M | 0.00 | -472.00K | 108.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.46M | 52.67M | -11.53M | -16.76M | 102.77M |